Citalopram or placebo alongside theta-burst stimulation for depression
About this title
Read the official source — NCT04846829Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 21 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Los AngelesSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 30
- Sponsor
- University of California, Los Angeles
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Device, Drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 21 Years to 55 Years
- Official registry ID
- NCT04846829
- Official title
Show the full official title
Acute Neurophysiologic Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)
Recruitment & locations
Los Angeles
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of California, Los Angeles, a university.
Does this study involve medication?
Yes. The study involves medication, including Placebo and intravenous citalopram hydrochloride (CIT).
Who can participate?
This study is for people with depression. Listed age limits: 21 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
